Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 3
---
us supplement. Prospective purchasers of our securities are
urged to obtain current information as to the market prices of our securities, where applicable.

We are a “foreign private issuer” as defined under the federal securities laws, and, as such, we will be subject to reduced public company reporting requirements. See the section entitled “Prospectus Summary—Implications of Being a Foreign Private Issuer” for additional information.

As of September 25, 2025,
the aggregate market value of our outstanding ordinary shares held by non-affiliates, or public float, was approximately $5,451,803, based
on 61,952,306,157 of our Ordinary Shares outstanding held by non-affiliates, and a per share price of approximately $0.000088, which represents
1/100,000 of $8.80, which was the price of our Depositary Shares on July 28, 2025, and which was the highest reported closing sale price
of our Depositary Shares on The NASDAQ Capital Market, the principal market for our common equity, in the 60 days prior to September 25,
2025. We have not offered any securities pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that
ends on and includes the date of this prospectus. Pursuant to General Instruction I.B.5. of Form F-3, in no event will we sell securities
registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float
in any 12-month period so long as our public float remains below $75 million.

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have described on page 7 of this prospectus under the caption “Risk Factors.” We may also include specific risk factors in supplements to this prospectus under the caption “Risk Factors.” This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is , 2025.</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                      | Page |
| ABOUT THIS PROSPECTUS